Exploiting host kinases to combat dengue virus infection and disease.

Antiviral Res

Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA, 98101, United States; Department of Pediatrics, University of Washington, Seattle, WA, 98195, United States; Department of Biochemistry, University of Washington, Seattle, WA, 98195, United States. Ele

Published: September 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The burden of dengue on human health has dramatically increased in recent years, underscoring the urgent need for effective therapeutic interventions. Despite decades of research since the discovery of the dengue virus, no specific antiviral treatments are available and strategies to reliably prevent severe disease remain limited. Direct-acting antivirals against dengue are under active investigation but have shown limited efficacy to date. An underappreciated Achille's heal of the virus is its dependence on host factors for infection and pathogenesis, each of which presents a potential avenue for therapeutic intervention. We and others have demonstrated that dengue virus relies on multiple host kinases, some of which are already targeted by clinically approved inhibitors. These offer drug repurposing opportunities for host-directed dengue treatment. Here, we summarize findings on the role of kinases in dengue infection and disease and highlight potential kinase targets for the development of innovative host-directed therapeutics.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12245208PMC
http://dx.doi.org/10.1016/j.antiviral.2025.106172DOI Listing

Publication Analysis

Top Keywords

dengue virus
12
host kinases
8
infection disease
8
dengue
7
exploiting host
4
kinases combat
4
combat dengue
4
virus
4
virus infection
4
disease burden
4

Similar Publications

Objective: To analyze the temporal trend of dengue incidence and lethality rates and the proportions of its serotypes, in the different macro-regions of Brazil, between 2001 and 2022. In particular, the immediate and gradual effects of these indicators were verified in the periods before and after the publication of the National Guidelines for the Prevention and Control of Dengue Epidemics.

Methods: This was an interrupted time series analysis.

View Article and Find Full Text PDF

Dengue Virus Biosafety: An Analysis of Evidence, Global Inconsistencies, and Risk Gaps.

Appl Biosaf

August 2025

Mahidol-Oxford Tropical Research Medicine Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Introduction: Dengue virus (DENV) poses a significant global health threat, particularly in tropical and subtropical regions, where it is primarily transmitted by spp. mosquitoes. Its biosafety and biosecurity management present unique challenges due to both its vector-borne nature and rare instances of nonvector transmission.

View Article and Find Full Text PDF

Identification of multifunctional T-cell peptide epitopes for the development of DNA vaccines against dengue virus.

Hum Vaccin Immunother

December 2025

Beijing Institute of Tropical Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory for Research on Prevention and Treatment of Tropical Diseases, Beijing, China.

Dengue virus (DENV) is an important arthropod-borne virus that poses a global health threat, with half of the world's population at risk of infection. Currently, there is a lack of safe and effective vaccines for its prevention. Antibody-dependent enhancement (ADE) occurs when cross-reactive antibodies fail to neutralize heterologous DENV serotypes effectively, facilitating viral entry into Fc receptor-bearing cells and leading to more severe disease.

View Article and Find Full Text PDF

Dengue virus infection reprograms baseline innate immune gene expression.

Med

September 2025

Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore 169856, Singapore; Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore; Department of Clinical Translational Research, Singapore General Hospital, Singapo

Background: All three dengue vaccines that have completed phase 3 clinical trials have shown greater efficacy in dengue-seropositive compared to dengue-seronegative individuals. This includes the live-attenuated tetravalent dengue vaccine TAK-003, where immunogenicity in baseline seronegative individuals remains lower after two doses, despite seroconversion after the first dose, compared to baseline seropositive individuals after one dose.

Methods: A whole-genome microarray was used to analyze the host response to TAK-003.

View Article and Find Full Text PDF